Kilic, Ayse https://orcid.org/0000-0002-9369-8377
Ozturan, Gokhan https://orcid.org/0000-0002-7874-3512
Vandekerkhove, Dirk
Kuenen, Sabine https://orcid.org/0000-0001-9135-5293
Swerts, Jef https://orcid.org/0000-0002-3380-6030
Muñoz Pedrazo, Esther https://orcid.org/0000-0002-7095-1851
Calatayud Aristoy, Carles
Escamilla Ayala, Abril https://orcid.org/0000-0002-5761-0999
Corthout, Nikky https://orcid.org/0000-0003-1176-7277
Hernández Varas, Pablo https://orcid.org/0000-0001-8664-9203
Plaisance, Stéphane https://orcid.org/0000-0002-1651-241X
Uytterhoeven, Valerie https://orcid.org/0000-0003-3100-2079
Nachman, Eliana https://orcid.org/0000-0002-2069-6469
Verstreken, Patrik https://orcid.org/0000-0002-5073-5393
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (11E2223N)
Fonds Wetenschappelijk Onderzoek (1165925N)
Fonds Wetenschappelijk Onderzoek (151095)
Fonds Wetenschappelijk Onderzoek (11O3225N)
Fonds Wetenschappelijk Onderzoek (1282123N)
Fonds Wetenschappelijk Onderzoek (G031324N)
Fonds Wetenschappelijk Onderzoek (G0B8119N)
EC | European Research Council (AdG 101054310)
Chan Zuckerberg Initiative
Methusalem Grant from the Flemish Government
KU Leuven Parkinson Fonds
Article History
Received: 10 December 2024
Revised: 6 July 2025
Accepted: 25 July 2025
First Online: 21 August 2025
Disclosure and competing interests statement
: PV is the scientific founder of Jay Therapeutics. The remaining authors declare no competing interests.